Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is associated with higher mortality and morbidity, and it most frequently has a functional cause. Furthermore, it has been proven that tricuspid surgery has mortality rates between 8% and 20%. On the other hand, it has been verified that, in the case of left-sided disease affecting the...
Courtesy of the SBHCI. Discover the results of the this study, presented during TCT Congress 2019. Link to the SBHCI publication HERE Original Title: A Propensity Score-Matched Analysis of Transcatheter Tricuspid Valve Treatment vs. Medical Treatment in Patients With Severe Tricuspid Regurgitation. Author of the original title: Maurizio Taramasso. We are interested in your opinion. Please,...
Patients with isolated tricuspid regurgitation (i.e., who have no associated left-sided valve disease) are frequently treated conservatively. In many cases, valve disease is highly symptomatic, even with the optimization of medical treatment; however, an invasive strategy is seldom proposed. The aim of this work was to measure the impact of surgery on isolated tricuspid regurgitation...
Courtesy of Dr. Carlos Fava. Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution. A meta-analysis of 12 studies with a total 41485 patients was carried out. ...
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) has a negative impact in the long run. Several reports have shown that, in high risk inoperable patients, transcatheter edge-to-edge valve repair with MitraClip is feasible, safe and has good results, but there is still a long way to go. The present study looked at 24 consecutive...
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR), both isolated or associated with other left valve diseases, has been associated with higher rates of heart failure hospitalization and of cardiovascular death. Recent studies in elderly high-risk patients who underwent percutaneous treatment of left valve disease have shown the presence of TR to be associated with...
Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table. Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices. The TRICENTO has an...
Transcatheter therapy offers a promise for a largely forgotten valve given the lack of therapeutic options. Percutaneous edge-to-edge repair with clip seems to offer some hope to patients with tricuspid regurgitation according to the TRILUMINATE. At 30 days, transcatheter repair with clip significantly reduced tricuspid regurgitation at least in one grade in most patients, which...
Tricuspid valve transcatheter edge-to-edge repair (T-TEER) is currently under development, with an increasing number of conducted procedures. While the TRILUMINATE Study did not reveal benefit regarding major events, it did show improvements in quality of life. In the real world, we encounter numerous patients who do not meet the study criteria but still experience symptoms...
Treating tricuspid regurgitation (TR) has gained increasing importance in interventionism. There is abundant literature on the negative natural evolution of this condition and its unfavorable prognosis, as well as the clinical challenges associated to optimal medical treatment. Among its percutaneous treatment options, both edge-to-edge repair devices (TEER), as showed in TriValve and TRILUMINATE trials, and...